// App-Quantinova.ai

120 : Predictors of Early Minimal Disease Activity in PsA Patients Treated with Anti-TNF in a Real-World Registry

Researchers

Presenter

  • Proton Rahman

Principal Investigators

  • Regan Arendse

  • Brendan Osborne

  • Karina Maslova

  • Francois Nantel

  • Allen Lehman

  • Cathy Tkaczyk

  • Michael Starr

  • John Kelsall

  • Antonio Avina-Zubieta

  • Philip Baer

  • Dalton Sholter

  • Michelle Teo

  • Emmanouil Rampakakis

  • Eliofotisti Psaradellis

Medical Centers

  • University of Alberta, Edmonton, AB, Canada

  • Memorial University, St. John's, NF, Canada

  • Universite de Montreal, Departement de medecine, Montreal,Canada

  • Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada

  • Penticton,Canada

  • Arthritis Research Centre of Canada, Richmond, BC, Canada

  • University of Saskatchewan, Saskatoon, SK, Canada

  • McGill, Montreal, QC, Canada

Locations

  • Canada

Companies

  • JSS Medical Research

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Rheumatoid arthritis

  • Inflammatory Arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Infliximab

  • golimumab

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved